“…Aspirin reduces blood glucose in patients with
T2DM (390) but not in individuals
with normal glucose tolerance (142,
337). More recently, several
studies, including six randomized, blinded and placebo controlled trials,
demonstrated marked improvements in glucose tolerance and reduced HbA1c with
salsalate treatment among obese patients with and without T2DM (13, 117, 130, 143–145, 196). In addition, in five of the six trials, salsalate treatment
reduced markers of systemic inflammation (CRP, IL-6, or CD40L) or increased
adiponectin (13, 130, 143,
145, 196).…”